Search PubMed⌕ Search

Biomedical subjects

C Towers

Publications and source records attributed to C Towers.

3 recordsLinked to original sources

Identifying poststreptococcal glomerulonephritis.

Expedient antimicrobial treatment of group A beta-hemolytic streptococcal tonsillopharyngitis prevents suppurative complications and rheumatic fever; however, timely therapy does not prevent acute poststreptococcal glomerulonephritis. Acute poststreptococcal glomerulonephritis is the most common form of postinfectious glomerulonephritis and a leading cause of acute and chronic renal failure in childhood. This article discusses clinical presentation, diagnostic workup, treatment, and prevention of poststreptococcal glomerulonephritis in adults and children in the primary care setting.

Glomerulonephritis↗

Performance of the dipalmitoyl phosphatidylcholine test in predicting respiratory distress syndrome in contaminated samples of amniotic fluid.

OBJECTIVE: To evaluate the reliability of the dipalmitoyl phosphatidylcholine test in predicting respiratory distress syndrome (RDS) in the presence of common contaminants of amniotic fluid. METHODS: Forty specimens of amniotic fluid collected within 72 hours of delivery were divided in five 25 microL aliquots and diluted with either phosphate-buffered saline (control), meconium, blood, vaginal fluid, or semen. The concentration of dipalmitoyl phosphatidylcholine in all five groups of samples, as measured by the dipalmitoyl phosphatidylcholine test, was compared by paired t test, Dunnett test, and analysis of variance, and correlated with the neonatal respiratory status of the newborns. RESULTS: No significant differences in the concentration of dipalmitoyl phosphatidylcholine were found between control and the corresponding contaminated samples (P = .33). Of the 200 samples evaluated, 80 had dipalmitoyl phosphatidylcholine concentrations below 12 micrograms/mL and 120 had at least 12 micrograms/mL. Using a cutoff dipalmitoyl phosphatidylcholine concentration of 12 micrograms/mL, the presence of RDS was predicted accurately in all 15 control and in 61 of 65 contaminated samples. The absence of RDS, as predicted by a dipalmitoyl phosphatidylcholine value at least 12 micrograms/mL, was predicted accurately in 24 of 25 control samples and 96 of 100 contaminated samples. The overall accuracy of the dipalmitoyl phosphatidylcholine test in predicting RDS in contaminated samples was 98%. CONCLUSION: The dipalmitoyl phosphatidylcholine test is a reliable predictor of RDS in contaminated samples.

1,2-Dipalmitoylphosphatidylcholine↗

Experiences in method development for the analysis of in vitro study solutions for content.

Effects of drugs on the cardiovascular system are required to be assessed as part of safety pharmacology, in particular using the in vitro Human Ether-a-go-go Related Gene Product (HERG) and Purkinje fibre studies and can be used to predict safety margins prior to administration to man. Recent International Conferences on Harmonization (ICH) regulations, draft ICHS7B guidelines, indicate that levels of drug in bath solutions used should be measured if quantitative data are to be obtained for the estimation of safety margins. To accurately measure drug concentrations in bath solutions, a validated analytical method is required. This method is required to be accurate, precise, specific, and robust, and due to the increased potency of new drugs, liquid chromatography with mass spectrometric detection (LC-MS) has become the method of choice. Recent experiences validating methods for the analysis of a wide range of drugs in bath solutions has presented a major issue regarding the solubility of some drugs in bath solutions. This has resulted in the requirement of a different approach to the analysis of, in particular, lipophilic drugs that has in turn highlighted the potential for the significant overestimation of the drug concentration in these bath solutions and therefore inaccurate calculation of safety margins.

Calibration↗